Abstract 13981: Aspirin Dose and Risk of Hypertensive Disorders of Pregnancy: A Propensity Score-Matched Real-World Analysis
Abstract
Introduction/Background: Hypertensive disorders of pregnancy remain a major cause of maternal and fetal morbidity, and aspirin is widely used for preeclampsia risk reduction. However, the optimal aspirin dose in real-world pregnancy care remains uncertain, and comparative effectiveness data evaluating higher-dose versus low-dose aspirin are limited. Research Question/Hypothesis: We hypothesized that higher-dose aspirin exposure would be associated with lower risk of hypertensive disorders of pregnancy compared with low-dose aspirin. Methods/Approach: We conducted a retrospective cohort study using the TriNetX Global Collaborative Network, which includes electronic health record data from 172 healthcare organizations. Adult patients aged ≥18 years with a documented pregnancy-related encounter from January 1, 2005 to December 31, 2025 were identified. Patients with chronic kidney disease, pre-existing hypertensive disorders, antiphospholipid syndrome, or systemic lupus erythematosus were excluded to reduce confounding from high-risk conditions and potential non-preeclampsia aspirin indications. Patients were stratified by aspirin dose recorded in the EHR: higher-dose aspirin (300-325 mg) versus low-dose aspirin (75-81 mg). Aspirin exposure was defined within 3 months before to 6 months after the most recent documented pregnancy-related event. The index event was the first documented pregnancy-related encounter. Outcomes were assessed from 1 to 365 days after index, excluding patients with the respective outcome before the time window. Primary outcomes were incident preeclampsia and gestational hypertension. Propensity score matching used demographics, comorbidities, and labs. Risk ratios (RR) with 95% confidence intervals (CI) were calculated, with low-dose aspirin as the reference group. Results/Data: Before matching, 1,552 patients were identified in the higher-dose aspirin cohort and 38,135 in the low-dose aspirin cohort. After matching, 1,537 patients remained in each cohort. Higher-dose aspirin was associated with lower risk of incident preeclampsia (1.1% vs 3.3%; RR 0.34, 95% CI 0.19-0.61; p<0.001) and gestational hypertension (1.3% vs 2.8%; RR 0.45, 95% CI 0.26-0.80; p=0.005). Kaplan-Meier analyses showed higher outcome-free survival for both endpoints in the higher-dose aspirin group. Conclusion(s): In this propensity score-matched real-world analysis, higher-dose aspirin exposure was associated with lower subsequent risk of incident preeclampsia and gestational hypertension compared with low-dose aspirin. Prospective studies with confirmed gestational timing, medication adherence are warranted.